Product Code: GVR-3-68038-791-9
Clinical Oncology NGS Market Growth & Trends
The global clinical oncology next generation sequencing market size is expected to reach USD 892.61 million by 2028 registering a CAGR of 14.70%, according to a new report by Grand View Research, Inc. Technological advancements in next-generation sequencing coupled with high adoption of companion diagnostics and personalized medicine drive the global market growth.
In addition, a rise in the utility of next generation sequencing (NGS) for liquid biopsy is expected to increase revenue generation in the market. NGS is employed to sequence circulating tumor DNA (ctDNA) for the analysis of liquid biopsy samples. This leads to efficient molecular profiling of tumors, which, in turn, facilitates real-time, non-invasive monitoring of tumors.
Moreover, a rise in market competitiveness, growth in oncology diagnostics spending, and increasing research activities to develop solutions that can potentially be used for clinical oncology drive market progression. For instance, in January 2021, Spectrum Solutions, LLC collaborated with the UCLA School of Dentistry on saliva-based NGS liquid biopsy research, which would be used for early diagnosis of Non-Small Cell Lung Cancer (NSCLC).
North America dominated the global market in 2020 owing to multiple initiatives taken by various government bodies in the region to screen and prevent cancer, such as Cancer Prevention and Control Research Network, a flagship program by the CDC. Asia Pacific is projected to be the fastest-growing regional market over the forecast period owing to continuous reforms in the pharmaceutical and life sciences industries in the region.
Key players in this market have undertaken strategic alliances to strengthen their market position. For example, in March 2020, Thermo Fisher Scientific signed an agreement with Janssen Biotech, Inc. for the development of CDx for tumor management. Under the agreement, Janssen Research & Development, LLC would validate multiple biomarkers to be used with Thermo Fisher's Oncomine Dx target test for identification of patients with NSCLC
Clinical Oncology NGS Market Report Highlights
- Targeted sequencing & resequencing accounted for the largest market share in 2020 owing to the high adoption of targeted gene panels for oncology diagnostics
- Moreover, the discovery of novel cancer biomarkers further boosts the development of targeted sequencing oncology panels
- Whole-Genome Sequencing (WGS) is projected to register the fastest growth rate from 2021 to 2028 as the technology offers a complete genomic survey of the tumor genome
- This helps in the generation of a detailed map of indels, copy number changes, Single Nucleotide Variations (SNV), and complex structural rearrangements with a single assay
- Companion diagnostics is projected to be the fastest-growing application segment from 2021 to 2028 owing to the high adoption and benefits offered by the technology
- Therefore, major market participants focus on innovative R&D in companion diagnostics to gain approval for novel tests
- For instance, in August 2020, the FDA approved Guardant360 CDx assay; an NGS-based liquid biopsy CDx to identify Epidermal Growth Factor Receptor (EGFR) gene mutations in metastatic NSCLC
Table of Contents
Chapter 1 Executive Summary
Chapter 2 Research Methodology
- 2.1 Information Procurement
- 2.2 Information or Data Analysis
- 2.3 Market Formulation & Validation
Chapter 3 Market Variables, Trends & Scope
- 3.1 Market Segmentation & Scope
- 3.2 Business segment trends
- 3.2.1 Penetration & Growth Prospect Mapping For Application, 2020
- 3.2.2 Penetration & Growth Prospect Mapping For Prominent Industry Players, 2020
- 3.3 Market variables analysis
- 3.3.1Market driver analysis
- 3.3.1.1 Decrease in costs for genetic sequencing
- 3.3.1.2 Advancements in the field of personalized medicine
- 3.3.1.3 Rise in competition amongst prominent market entities
- 3.3.1.4 Growing healthcare expenditure triggering development of effective PM diagnostic & therapeutic procedure for cancer
- 3.3.1.5 Rise in prevalence of cancer
- 3.3.1.6 Growing adoption of NGS over single gene testing
- 3.3.2 Market restraint analysis
- 3.3.2.1 Lack of computational efficiency for data management
- 3.3.2.2 Non-value based NGS reimbursement policy
- 3.4 Business environment analysis tools
- 3.4.1 Swot Analysis, By Factor (Political & Legal, Economic And Technological)
- 3.4.2Porter's five forces analysis
- 3.5 Impact of COVID-19 on Market Growth
- 3.6 Next-Generation Sequencing Reimbursement Environment
- 3.7 Regulatory and Political Environment
Chapter 4 Competitive & Vendor Landscape
- 4.1 Strategy Framework
- 4.2 Market Participation Categorization
Chapter 5 Clinical Oncology Next Generation Sequencing Market Categorization: Technology Estimates & Trend Analysis
- 5.1 Clinical Oncology NGS Market: Technology movement analysis
- 5.2 Whole Genome Sequencing
- 5.2.1Whole genome sequencing for clinical oncology market, 2017 - 2028 (USD Million)
- 5.3 Whole Exome Sequencing
- 5.3.1 Whole exome sequencing for clinical oncology market, 2017 - 2028 (USD Million)
- 5.4 Targeted Sequencing & Resequencing
- 5.4.1 Targeted sequencing and resequencing for clinical oncology market, 2017 - 2028 (USD Million)
Chapter 6 Clinical Oncology Next Generation Sequencing Market Categorization: Workflow Estimates & Trend Analysis
- 6.1 Clinical Oncology NGS Market: Workflow Movement Analysis
- 6.2 NGS Pre-Sequencing
- 6.2.1 NGS pre-sequencing for clinical oncology market, 2017 - 2028 (USD Million)
- 6.3 NGS Sequencing
- 6.3.1 NGS sequencing for clinical oncology market, 2017 - 2028 (USD Million)
- 6.4 NGS Data Analysis
- 6.4.1 NGS data analysis for clinical oncology market, 2017 - 2028 (USD Million)
Chapter 7 Clinical Oncology Next Generation Sequencing Market Categorization: Application Estimates & Trend Analysis
- 7.1 Clinical Oncology NGS Market: Application Movement Analysis
- 7.2 Screening
- 7.2.1 Screening clinical oncology NGS market, 2017 - 2028 (USD Million)
- 7.2.2 Sporadic Cancer
- 7.2.2.1 Sporadic cancer screening clinical oncology NGS market, 2017 - 2028 (USD Million)
- 7.2.3Inherited cancer
- 7.2.3.1 Inherited cancer screening clinical oncology NGS market, 2017 - 2028 (USD Million)
- 7.3 Companion Diagnostics
- 7.3.1 Companion diagnostics clinical oncology NGS market, 2017 - 2028 (USD Million)
- 7.4 Other Diagnostics
- 7.4.1 Other diagnostics clinical oncology NGS market, 2017 - 2028 (USD Million)
Chapter 8 Clinical Oncology Next Generation Sequencing Market Categorization: End Use Estimates & Trend Analysis
- 8.1 Clinical Oncology NGS Market: End Use Movement Analysis
- 8.2 Hospitals
- 8.2.1 Hospitals clinical oncology NGS market, 2017 - 2028 (USD Million)
- 8.3 Clinics
- 8.3.1 Clinics clinical oncology NGS market, 2017 - 2028 (USD Million)
- 8.4 Laboratories
- 8.4.1 Laboratories clinical oncology NGS market, 2017 - 2028 (USD Million)
Chapter 9 Clinical Oncology Next Generation Sequencing Market Categorization: Regional Estimates & Trend Analysis, by Technology, Workflow, Application, & End Use
- 9.1 Clinical Oncology NGS Market Share By Regional, 2018 & 2025
- 9.2 North America
- 9.2.1 North America clinical oncology NGS market, 2017 - 2028 (USD Million)
- 9.2.2 The U.S.
- 9.2.2.1 The U.S. clinical oncology NGS market, 2017 - 2028 (USD Million)
- 9.2.3Canada
- 9.2.3.1Canada clinical oncology NGS market, 2017 - 2028 (USD Million)
- 9.3 Europe
- 9.3.1 Europe clinical oncology NGS market, 2017 - 2028 (USD Million)
- 9.3.2 Germany
- 9.3.2.1 Germany clinical oncology NGS market, 2017 - 2028 (USD Million)
- 9.3.3 The U.K.
- 9.3.3.1 The U.K. clinical oncology NGS market, 2017 - 2028 (USD Million)
- 9.3.4 France
- 9.3.4.1 France clinical oncology NGS market, 2017 - 2028 (USD Million)
- 9.3.5 Italy
- 9.3.5.1 Italy clinical oncology NGS market, 2017 - 2028 (USD Million)
- 9.3.6Spain
- 9.3.6.1Spain clinical oncology NGS market, 2017 - 2028 (USD Million)
- 9.4 Asia Pacific
- 9.4.1Asia-Pacific clinical oncology NGS market, 2017 - 2028 (USD Million)
- 9.4.2Japan
- 9.4.2.1 Japan clinical oncology NGS market, 2017 - 2028 (USD Million)
- 9.4.3China
- 9.4.3.1 China clinical oncology NGS market, 2017 - 2028 (USD Million)
- 9.4.4India
- 9.4.4.1 India clinical oncology NGS market, 2017 - 2028 (USD Million)
- 9.4.5South Korea
- 9.4.5.1 South Korea clinical oncology NGS market, 2017 - 2028 (USD Million)
- 9.4.6Australia
- 9.4.6.1 Australia clinical oncology NGS market, 2017 - 2028 (USD Million)
- 9.5 Latin America
- 9.5.1 Latin America clinical oncology NGS market, 2017 - 2028 (USD Million)
- 9.5.2Brazil
- 9.5.2.1 Brazil clinical oncology NGS market, 2017 - 2028 (USD Million)
- 9.5.3Mexico
- 9.5.3.1 Mexico clinical oncology NGS market, 2017 - 2028 (USD Million)
- 9.6 Middle East & Africa (MEA)
- 9.6.1 Middle East & Africa clinical oncology NGS market, 2017 - 2028 (USD Million)
- 9.6.2 South Africa
- 9.6.2.1 South Africa clinical oncology NGS market, 2017 - 2028 (USD Million)
- 9.6.3 Saudi Arabia
- 9.6.3.1 Saudi Arabia clinical oncology NGS market, 2017 - 2028 (USD Million)
Chapter 10 Clinical Oncology NGS Market: Company Profiles
- 10.1 Key Companies Profiled
- 10.2 Illumina, Inc.
- 10.2.1 Company overview
- 10.2.1.1Financial performance
- 10.2.2 Product benchmarking
- 10.2.3 Strategic initiatives
- 10.3 F. Hoffmann-La Roche Ltd
- 10.3.1 Company overview
- 10.3.1.1Financial performance
- 10.3.2 Product benchmarking
- 10.3.3 Strategic initiatives
- 10.4 Agilent Technologies
- 10.4.1 Company overview
- 10.4.2 Financial performance
- 10.4.3 Product benchmarking
- 10.4.4 Strategic initiatives
- 10.5 Thermo Fisher Scientific Inc.
- 10.5.1 Company overview
- 10.5.2 Financial performance
- 10.5.3 Product benchmarking
- 10.5.4 Strategic initiatives
- 10.6 Myriad Genetics, Inc.
- 10.6.1 Company overview
- 10.6.2 Financial performance
- 10.6.3 Product benchmarking
- 10.6.4 Strategic initiatives
- 10.7 Beijing Genomics Institute (BGI)
- 10.7.1Company overview
- 10.7.2Financial performance
- 10.7.3Product benchmarking
- 10.7.4Strategic initiatives
- 10.8 Qiagen NV
- 10.8.1 Company overview
- 10.8.2 Financial performance
- 10.8.3 Product benchmarking
- 10.8.4 Strategic initiatives
- 10.9 Perkin Elmer, Inc.
- 10.9.1 Company overview
- 10.9.2 Financial performance
- 10.9.3 Product benchmarking
- 10.9.4 Strategic initiatives
- 10.10 Pacific Bioscience, Inc.
- 10.10.1 Company overview
- 10.10.2 Financial performance
- 10.10.3 Product benchmarking
- 10.10.4 Strategic initiatives
- 10.11 Partek, Inc.
- 10.11.1 Company overview
- 10.11.2 Financial performance
- 10.11.3 Product benchmarking
- 10.11.4 Strategic initiatives
- 10.12 Foundation Medicine Inc.
- 10.12.1 Company overview
- 10.12.2 Financial performance
- 10.12.3 Product benchmarking
- 10.12.4 Strategic Initiatives
- 10.13 Oxford Nanopore Technologies Ltd.
- 10.13.1 Company overview
- 10.13.2 Financial performance
- 10.13.3 Product benchmarking
- 10.13.4 Strategic Initiatives
- 10.14 Paradigm Diagnostics, Inc
- 10.14.1 Company overview
- 10.14.2 Financial performance
- 10.14.3 Product benchmarking
- 10.14.4 Strategic initiatives
- 10.15 Caris Life Sciences
- 10.15.1 Company overview
- 10.15.2 Financial performance
- 10.15.3 Product benchmarking
- 10.15.4 Strategic Initiatives
- 10.16 Eurofins Scientific S.E.
- 10.16.1 Company overview
- 10.16.2 Financial performance
- 10.16.3 Product benchmarking
- 10.16.4 Strategic initiatives
- 10.17 Perkin Elmer
- 10.17.1 Company overview
- 10.17.2 Financial performance
- 10.17.3 Product benchmarking
- 10.17.4 Strategic initiatives
比較リスト
